YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today ...

OBI-902, targeting TROP2, gains FDA orphan drug status for cholangiocarcinoma, a rare cancer with poor prognosis and limited treatments. Orphan drug designation provides benefits like tax credits and ...

The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.

ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported third-quarter financial results and outlined major clinical milestones that position the company for a pivotal two-year stretch focused on advancing ...

An update from Dermata Therapeutics ( ($DRMA) ) is now available. On November 17, 2025, Dermata Therapeutics announced the termination of its ...

An analysis of federal data shows a pronounced decline, despite alarming conditions found at some manufacturers.

Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...

A new study led by Yale's Jennifer Miller, PhD, found that medicines are not physically accessible in many of the countries where they are tested for FDA approval.

This NDA submission is an important milestone, and it brings gedatolisib one step closer to becoming available for patients with HR+/HER2- advanced breast cancer,” said Brian Sullivan, CEO and ...

A lawsuit filed over a man's overdose death at a former treatment facility is raising broader questions about why state ...

Merck said on Monday it expects a commercial opportunity exceeding $5 billion from Cidara Therapeutics' experimental flu drug ...

We believe that a partnership with Allucent, is a significant move forward in bringing our novel PTSD therapeutic to the clinic,” said Silo CEO Eric Weisblum. “With Allucent’s expertise, we believe ...